WHAT IS BHI

About us

Welcome to BHI Therapeutic Sciences, Inc. , an international biotechnology company that specializes in delivering the highest quality stem cell treatments for various conditions. We are committed to providing our patients with the most advanced therapy at the lowest cost point in the market. BHI has a team of world-class scientists and medical professionals who are dedicated to researching and developing new treatments for a wide range of health conditions. Our research efforts are led by a Scientific Advisory Board composed of some of the most accomplished scientists and medical professionals in the field of stem cell therapy. We have a wide network of clinics located in various geographic locations across the world, each one appropriately licensed to provide the best quality of care to our patients. We are currently engaged in a U.S. FDA Investigational New Drug (IND) trial for stroke using human umbilical cord blood stem cells, which is a testament to our commitment to advancing the field of medicine. We are proud to be at the forefront of medical innovation and to be part of the future of healthcare. Our goal is to bring the benefits of stem cell therapy to as many people as possible, and we are committed to providing our patients with the best possible care.

innovate
Innovative
BHI Therapeutic Sciences is at the forefront of biotechnology innovation, constantly researching and developing new treatments to improve the lives of our patients
biotech
Biotechnology
BHI Therapeutic Sciences Therapeutic Sciences is a biotechnology company that specializes in the field of stem cell therapy, using cutting-edge technology to provide advanced treatments.
advanced
Stem cell therapy
BHI Therapeutic Sciences Therapeutic Sciences offers the most advanced stem cell therapy treatments available, backed by unparalleled 10-year safety and efficacy data
intro
Why choose our stock

Invest in the future of healthcare by supporting BHI Therapeutic Sciences, the US entity of the Blue Horizon International family of companies. We are proud to offer a crowdfunding opportunity for investors who are passionate about biotechnology innovation. As a leading international company, BHI provides top-quality stem cell treatments for a variety of conditions, supported by a 10-year track record of safety and efficacy. Our network of licensed clinics offers cutting-edge therapy at an affordable price, while our world-class Scientific Advisory Board conducts research efforts to advance the field of stem cell therapy. Our advisors have already successfully treated thousands of patients and we are currently involved in a U.S. FDA-approved Investigational New Drug (IND) trial for the treatment of stroke using human umbilical cord blood stem cells. Join us on the forefront of medical advancement and be a part of shaping the future of healthcare.

Investment in cutting-edge biotechnology innovation

BHI Therapeutic Sciences offers the highest quality stem cell treatments for various conditions, backed by unparalleled 10-year safety and efficacy data, positioning it at the forefront of medical advancement.

World-class Scientific Advisory Board

BHI Therapeutic Sciences has assembled a world-class Scientific Advisory Board to lead research efforts globally and they have already treated thousands of patients using stem cell therapy.

Lowest cost point in the market

BHI Therapeutic Sciences offers cutting-edge therapy at the lowest cost point in the market through our network of clinics licensed in every geographic location.

Security & control over money

Provide high levels of security allowing the user to keep control money.
PROBLEM & SOLUTION

The Problem & Our Solution

Problem
Despite being a world-leading provider of stem cell therapies and being fully licensed by the Ministry of Health of the Slovak Republic, BHI Therapeutic Sciences is facing challenges in gaining widespread acceptance and recognition of its therapies in the medical community.
Solution
To increase acceptance and recognition of BHI's therapies, the company will focus on publishing and presenting their research at reputable medical conferences and journals. They will also work to gain accreditation from well-known organizations such as the Joint Commission International (JCI) and the International Society for Quality in Health Care (ISQua). BHI Therapeutic Sciences will also emphasize the safety and efficacy of its therapies by ensuring that their cellular products are collected in accordance with Good Tissue Practice, and that their clinical studies are conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Additionally, BHI Therapeutic Sciences will continue to pursue FDA approval for their therapies through the Investigational New Drug (IND) application process.
circles
pattern-layer
Allocation & Funds Distribution
Invest now
  • Funding Allocation
funds
Core BHI Therapeutic Sciences Staff Expenses: 14.77%
Setup Costs For All the Clinics: 206.34%
Misc Expenses: 29.55%
Ongoing Stem Cell Project Costs: 20.14%
Taxes: 2.3%
Emergency Funds: 27.02%
graph
circles

Start time

15 March 2023

Company

BHI

PRICE PER SHARE

$1.00

PRE VALUATION

120 M

AMOUNT RAISED

1.2 M

DEADLINE

30 Nov, 2023
OFFERING TYPE
COMMON
$1/share
MAX SUPPLY
12.0 M
$1/share
MIN INVESTMENT
$100 US Domestic
€100 International
$1/share
MAX INVESTMENT
$1,000,000.00
$1/share
SHARES OFFERED
Class B
$1/share
Road map

Our Strategy & Project Plan

Q1 2022
FDA
Expanded Access Compassionate Care IND applications filed
Q1 2023
FDA
Interact and Pre-IND Meetings to qualify for Fast Track Designation
Q3 2023
FDA
Initial IND filed
Q4 2023
FDA
Phase 1/2 Open Label trial begin
Q2 2024
FDA
Phase 3 Randomized, Double-Blind, Placebo trial begins
Q2 2025
FDA
BLA Review begin
Q1 2026
Benefits
FDA BLA Approval granted
Buisness plan

Overview

BHI Therapeutic Sciences is a healthcare consulting company that offers a unique blend of therapy, research, and philanthropy. The company provides the highest quality care and service in surgical and medical therapies globally, using the most advanced technologies in areas such as stem cell therapy, regenerative medicine, and cancer immunotherapy. Additionally, BHITS provides resources for those who are medically underserved. The company's research studies aim to measure the safety and efficacy of various stem cell therapies, using a combination of autologous and allogeneic stem cells to treat conditions such as spinal cord injury, traumatic brain injury, and chronic inflammation. The BHITS team is currently working on multiple stem cell research projects, some of which are in different stages of the U.S. FDA approval process. The company has already published several peer-reviewed stem cell research papers and is the only company to have received U.S. FDA approval for treating patients with stem cell therapies. With a global and innovative business model, BHITS is able to test its therapies in various locations, including the U.S., Jamaica, and Slovakia, and bring back data for quicker approvals from the U.S. FDA.
Business Plan
funds
circles
circle
OUR TEAM

The Leadership Team

founder
Dr. Brian Mehling
Founder, CMO
doreen
Doreen Santora
CEO
alan
Alan Pereira
President, BHI Brazi
katarina
Katarina Novakova
President, BHI Slovakia
klara
Klara Doert
President of international development
leandro
Leandro Silva
President, BHI Performance

Scientific Advisory Board

wu
Dongcheng Wu
Chief science officer Ph.D., Wuhan University, Wuhan, China
mike
Michael Platt
Ph.D., Biological Anthropology, University of Pennsylvania
vicky
Vicky Yamamoto
Ph.D. Chair of the SAB at BHI, Chair of the Board of Directors
FAQs

Frequently Questions

  • General
  • Equity Offering
  • Legal
What is Blue Horizon's focus and mission?
Blue Horizon's focus is on regenerative medicine and its mission is to become a global leader in the field via stem cell therapies.
What kind of stem cell therapies does Blue Horizon offer?
BHI Therapeutic Sciences uses Stem Cells which are harvested from Placental Cord material harvested at C-section with no injury to the baby or the mother. BHI Therapeutic Sciences never uses Stem Cells harvested from embryonic or fetal tissue. BHI Therapeutic Sciences’ Stem Cells doses are the highest available anywhere in the world with a dose of 100 million cultured Wharton’s jelly cells per dose.
How does Blue Horizon's research and development process work?
Blue Horizon conducts extensive research and development to identify and develop innovative stem cell therapies. They work closely with leading experts in the field to ensure that their therapies are safe and effective.
BHI Therapeutic Sciences has the most published peer review research of any Stem Cell provider, domestically or internationally
What are Blue Horizon's growth prospects?
Blue Horizon's innovative therapies and strong partnerships position the company for significant growth in the regenerative medicine market.
What is Blue Horizon's financial performance?
Blue Horizon has reported steady revenue growth and positive financial performance in recent years. The company has a strong balance sheet and is well-positioned for future growth.
What are the terms and conditions of the investment, such as the length of the investment and any potential risks involved?
The investment is in the form of equity, meaning the term is infinite and it is not a loan or convertible note. The risk involved is the complete loss of the investment.
What is the minimum investment amount?
The minimum investment amount is $1.
What are the potential returns for investors?
The potential returns for investors are not specified, but investors can expect an increase in valuation.
Is there any accreditation requirement for investors?
There is no accreditation requirement for investors.
Is there a cap on the investment amount?
There is no cap on the investment amount, but if an investor wants to invest millions, they will be evaluated for accredited investor status.
Are there any restrictions on who can invest, such as certain countries or regions?
There are no restrictions on who can invest, but the company is based in the USA.
We will soon be offering a crowdfunding opportunity in our sister company Blue Horizon International, which is a Luxenberg-based international company with plans to open in dozens of countries in the coming 12 to 24 months and already to open and functioning clinics.
Is there an exit strategy for investors?
The company plans to go public, and investors will be able to sell their shares on a public exchange.
Are legal or financial professionals involved in the investment process?
Yes, legal and financial professionals are involved in the investment process, and the offering is registered with the USA FDA.
Are there any legal or regulatory requirements that the investment page needs to comply with?
The investment opportunity is registered with the US SEC.
Is there any rewards system for investors?
There will be an award system offered to investors based on the dollar amount invested
What are the securities laws that Blue Horizon must comply with during the seed round of funding?
Blue Horizon must comply with federal and state securities laws, including the Securities Act of 1933 and the Securities Exchange Act of 1934. It's best to consult with a lawyer for more information.
What type of documentation will be required for an investor to participate in the seed round of funding for Blue Horizon?
An investor will likely be required to complete documentation such as a subscription agreement and investor questionnaire. It's best to consult with a lawyer or the company for more information.
What are the rights and responsibilities of the investors in Blue Horizon during the seed round?
The rights and responsibilities of the investors in Blue Horizon during the seed round will depend on the terms of the investment and the type of equity offered. It's best to consult with a lawyer or the company for more information.
What is the process for the investor to exit their investment in Blue Horizon
The process for an investor to exit their investment in Blue Horizon will depend on the terms of the investment and the type of equity offered. It may include options such as a secondary market sale or a buyback by the company. It's best to consult with a lawyer or the company for more information.
Portfolio

Our Porfolio

Explore Our Portfolio
ALPHA BLU Skincare
    Alpha Blu Skincare offers a range of anti-aging skin care products formulated with their proprietary ingredient, BlueCellule-CM™. This ingredient is derived from stem cell-conditioned medium and is known for its skin rejuvenation properties. The product line aims to improve skin firmness, elasticity, and overall appearance, targeting issues like fine lines, wrinkles, and uneven skin texture. The brand emphasizes the effectiveness of BlueCellule-CM™ in stimulating skin cell regeneration and its anti-inflammatory properties.
    Learn More
    Rejuve
      BHI Rejuve, led by Dr. Brian Mehling, specializes in anti-aging sciences and rejuvenation therapies. Certified by the American Academy of Anti-Aging Medicine, the company offers a range of services including hormone optimization programs for men and women, supplement protocols, chelation therapy, and stem cell research protocols. They focus on addressing symptoms like early menopause, low testosterone, and related health concerns, providing personalized treatments based on extensive lab assessments.
      Learn More
      BHI performance
        Description of Product 1. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
        Learn More